EU, Indian And US Leaders Share Global Outlook To 2030
Association Heads Set Out Views Following Launch Of IGBA ‘Vision’ Whitepaper
At an IGBA panel discussion moderated by Generics Bulletin’s editor, three industry leaders representing Europe, India and the US debated the key issues facing the international off-patent sector today.
You may also be interested in...
A whitepaper setting out a comprehensive vision for the off-patent industry to 2030 has been launched by the IGBA. Highlighting the industry’s current contribution to healthcare, it also sets out a path ahead for the generics and biosimilars sector, pointing out headwinds as well as opportunities.
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.
Off-patent industry players from around the globe now have an extra week to submit their achievements to the Global Generics & Biosimilars Awards 2021 being held on 10 November, after the entry deadline was extended by a week to 6 August. Pharmacloud has also joined the event, sponsoring the Leader of the Year category.